News

Location:Home > News > Industry news
Oral OTEZLA? (Apremilast) Monotherapy...
2014-07-28

Clinically meaningful improvements in enthesitis, dactylitis and physical function with OTEZLA seen at week 16 and were sustained for up to 52 weeks of treatment PALACE 4 is the first and only large...

Merck Strengthens Commitment to Chinese ...
2014-07-28

Merck, a leading company for high-tech products in the pharmaceutical and chemical sectors, today reiterated its commitment to investments in the Chinese market, strengthening a major pillar of its...

FDA approves new product to treat rare...
2014-07-28

The U.S. Food and Drug Administration yesterday approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks in adult and adolescent patients with...

Merck Announces Data from...
2014-07-28

known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the safety and efficacy of EMEND? (aprepitant) in the prevention of ...

Forest to Present Aclidinium Bromide and...
2014-07-28

NEW YORK (BUSINESS WIRE) Forest Laboratories, Inc (NYSE: FRX) today announced that they will present data related to aclidinium bromide and roflumilast at the American Thoracic Society (ATS)...

apex英雄官网手游 澳洲幸运5 360彩票全国安全购彩 重庆时时彩龙综合走势图 东北麻将 吃 叉 和 顺序 江西快三 14场胜负彩奖金预测 安徽十一选五 丰禾棋牌备用 智能马桶盖赚钱 电视广告赚钱游戏 北京赛车pk10 新快3客服 山东时时彩 浙江快乐12一定牛预测 篮球比分即时比分直播 89彩票苹果